Processa Pharmaceuticals (PCSA) Competitors $0.87 +0.03 (+4.04%) (As of 03:33 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PCSA vs. TLPH, PHXM, TSBX, MYNZ, KPRX, BCDA, VIRX, INDP, AYTU, and CYCNShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Talphera (TLPH), PHAXIAM Therapeutics (PHXM), Turnstone Biologics (TSBX), Mainz Biomed (MYNZ), Kiora Pharmaceuticals (KPRX), BioCardia (BCDA), Viracta Therapeutics (VIRX), Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Talphera PHAXIAM Therapeutics Turnstone Biologics Mainz Biomed Kiora Pharmaceuticals BioCardia Viracta Therapeutics Indaptus Therapeutics Aytu BioPharma Cyclerion Therapeutics Talphera (NASDAQ:TLPH) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Does the MarketBeat Community believe in TLPH or PCSA? Processa Pharmaceuticals received 9 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTalpheraOutperform Votes6100.00% Underperform VotesNo VotesProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Do analysts prefer TLPH or PCSA? Talphera presently has a consensus target price of $4.50, indicating a potential upside of 627.80%. Processa Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 588.86%. Given Talphera's stronger consensus rating and higher possible upside, research analysts plainly believe Talphera is more favorable than Processa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TLPH or PCSA more profitable? Talphera's return on equity of -118.46% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -118.46% -65.82% Processa Pharmaceuticals N/A -195.21%-163.06% Do institutionals & insiders have more ownership in TLPH or PCSA? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. 3.2% of Talphera shares are owned by company insiders. Comparatively, 13.0% of Processa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better valuation and earnings, TLPH or PCSA? Processa Pharmaceuticals has lower revenue, but higher earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$281K37.47-$18.40M-$0.69-0.90Processa PharmaceuticalsN/AN/A-$11.12M-$3.39-0.26 Which has more volatility & risk, TLPH or PCSA? Talphera has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Does the media refer more to TLPH or PCSA? In the previous week, Processa Pharmaceuticals had 2 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Processa Pharmaceuticals and 0 mentions for Talphera. Talphera's average media sentiment score of 0.00 beat Processa Pharmaceuticals' score of -0.59 indicating that Talphera is being referred to more favorably in the media. Company Overall Sentiment Talphera Neutral Processa Pharmaceuticals Negative SummaryTalphera beats Processa Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Insiders ExposedNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.74M$6.71B$5.22B$9.27BDividend YieldN/A3.00%5.12%4.29%P/E Ratio-0.2610.5887.4217.27Price / SalesN/A195.781,166.39119.60Price / CashN/A57.1543.2337.83Price / Book0.225.164.834.93Net Income-$11.12M$151.58M$120.46M$225.34M7 Day Performance-13.76%-0.64%-0.26%1.13%1 Month Performance1.27%-3.02%15.99%2.76%1 Year Performance-90.31%8.81%30.22%16.90% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals3.0992 of 5 stars$0.87+4.0%$6.00+588.9%-90.7%$2.74MN/A-0.2620Gap DownTLPHTalphera2.9578 of 5 stars$0.63-1.6%$4.50+620.0%N/A$10.64M$281,000.00-0.9119Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049TSBXTurnstone Biologics2.9135 of 5 stars$0.45-8.3%$2.13+371.9%-84.9%$10.42M$19.31M-0.1482Positive NewsGap DownMYNZMainz Biomed2.5125 of 5 stars$5.01-25.0%$120.00+2,295.2%-89.7%$10.03M$917,203.00-0.0830High Trading VolumeKPRXKiora Pharmaceuticals2.9681 of 5 stars$3.29+0.6%$10.00+204.0%-32.2%$9.87M$16M0.0010News CoverageBCDABioCardia3.3486 of 5 stars$2.06+4.6%$25.00+1,113.6%-79.4%$9.44M$71,000.00-0.4916Positive NewsGap UpVIRXViracta Therapeutics2.5996 of 5 stars$0.23+9.8%$5.00+2,069.2%-53.6%$9.16MN/A-0.2120Gap UpINDPIndaptus Therapeutics2.9356 of 5 stars$0.88-6.2%$8.50+865.8%-53.2%$8.97MN/A-0.516News CoverageAYTUAytu BioPharma0.9243 of 5 stars$1.45+4.8%N/A-50.2%$8.90M$79.76M-1.18160CYCNCyclerion Therapeutics0.6705 of 5 stars$3.19flatN/A-25.6%$8.65M$194,000.000.0030Gap Down Related Companies and Tools Related Companies Talphera Alternatives PHAXIAM Therapeutics Alternatives Turnstone Biologics Alternatives Mainz Biomed Alternatives Kiora Pharmaceuticals Alternatives BioCardia Alternatives Viracta Therapeutics Alternatives Indaptus Therapeutics Alternatives Aytu BioPharma Alternatives Cyclerion Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCSA) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
